When was Ocelot Bio founded?

Ocelot Bio was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Where is Ocelot Bio located?

Ocelot Bio is headquartered in San Diego, United States.

How many employees does Ocelot Bio have?

As of Jul 01, 2024, the latest employee count at Ocelot Bio is 13.

Is Ocelot Bio a funded company?

Ocelot Bio is a funded company, having raised a total of $***** in its 1st and only funding round, a Series A round on Apr 13, 2021.

When was the latest funding round of Ocelot Bio?

Ocelot Bio's latest funding was a $***** Series A round on Apr 13, 2021, with participation from 3 investors. Its primary sector is Biopharma Outsourcing. In United States, the Biopharma Outsourcing sector has seen $408M in funding in 2026 to date.

Where does Ocelot Bio rank among its competitors?

Ocelot Bio ranks 9th amongst 65 active competitors, of which 8 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Enzene, which secured $50M in Jan, 2023.

Who are the top competitors of Ocelot Bio?

Ocelot Bio's top competitors include Enzene, Shaanxi Micot Technology and PolyPeptide. Among them, Enzene secured the most recent funding round in January, 2023.

Ocelot Bio - 2026 Company Profile, Team, Funding & Competitors

Ocelot Bio is a deadpooled company based in San Diego (United States), founded in 2020 by Gebhard Neyer and Geoff Harris. It operates as a CDMO focused on manufacturing of peptides. Ocelot Bio has raised $36M in funding from investors like Venrock, RA Capital Management and Vivo Capital. The company has 65 active competitors, including 8 funded and 9 that have exited. Its top competitors include companies like Enzene, Shaanxi Micot Technology and PolyPeptide.

Company Details

Website: ocelotbio.com
Social

Key Metrics

Founded Year

2020

Location

San Diego, United States

Stage

Deadpooled

Total Funding

$36M in 1 round

Latest Funding Round

Series A, Apr 13, 2021, $*****

Investors

Venrock & 2 more

Ranked

9^th among 65 active competitors

Employee Count

13 as on Jul 01, 2024

Similar Companies

Enzene & 72 more

View Ocelot Bio's full profile

Ocelot Bio has raised a total funding of $36M over 1 round. Its latest funding round was a Series A round on Apr 13, 2021 for $*****. 3 investors participated in its latest round. Ocelot Bio has 3 institutional investors.

Here is the list of recent funding rounds of Ocelot Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 13, 2021	9862240	Series A	7987358	2033692	2889920	4933700

Access funding benchmarks and valuations. Sign up today!

View details of Ocelot Bio's funding rounds and investors

The founders of Ocelot Bio are Gebhard Neyer and Geoff Harris.

Here are the details of Ocelot Bio's key team members:

Gebhard Neyer: Founder & COO of Ocelot Bio.
Contact Info: 1 email address
Geoff Harris: Founder & CEO of Ocelot Bio.
Contact Info: 1 email address

View details of Ocelot Bio's Founder profiles and Board Members

Ocelot Bio's employee count trend

Ocelot Bio has 13 employees as of Jul 24. Here is Ocelot Bio's employee count trend over the years:

Uncover Ocelot Bio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ocelot Bio include Enzene, Shaanxi Micot Technology and PolyPeptide. Here is the list of Top 10 competitors of Ocelot Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Enzene 2015, Pune (India), Series C	Company specializing in development of Biosimilars	$50M	F-Prime Capital, Eight Roads Ventures & 1 others	53/100
2nd	Shaanxi Micot Technology 2007, China, Series B	Provider of drug research and development services focused on cardiovascular and metabolic diseases	$72.2M	NLVC, Tasly & 2 others	46/100
3rd	PolyPeptide 1952, Baar (Switzerland), Public	CMO manufacturing proprietary,GMP grade and non-GMP-grade peptides	-	-	44/100
4th	Hybio Pharmaceutical 1998, Shenzhen (China), Public	Developer and manufacturer of polypeptide drugs and APis	$15M	Shenzhen Capital Group, SAIF Partners & 1 others	43/100
5th	Custom Peptide Synthesis 2011, Mumbai (India), Unfunded	Manufacturer of peptides and other finished formulations, & APIs	-	-	40/100
6th	AmbioPharm 2006, North Augusta (United States), Series B	Peptide manufacturing and development services, setting a new standard worldwide	$24M	The Carlyle Group, MVM	39/100
7th	USV Peptides 2011, Mumbai (India), Unfunded	CDMO offering custom peptide, GMP peptide and cosmetic peptide synthesis services	-	-	34/100
8th	JPT Peptide 2004, Berlin (Germany), Acquired	Peptide based CRO offering proteomics, biomarker and drug discovery services	-	-	32/100
9th	Ocelot Bio 2020, San Diego (United States), Deadpooled	CDMO focused on manufacturing of peptides	$36M	RA Capital Management, Vivo Capital & 1 others	32/100
10th	vivitide 1983, Gardner (United States), Acquired	Provider of drug development services for neoantigen peptide and antibody services	-	Ampersand Capital	31/100